Abstract
Recent findings indicate an important role for RNA-mediated gene expression in motor neuron diseases, including ALS (amyotrophic lateral sclerosis) and SMA (spinal muscular atrophy). ALS, also known as Lou Gehrig’s disease, is an adult-onset progressive neurodegenerative disorder, whereby SMA or “children’s Lou Gehrig’s disease” is considered a pediatric neurodevelopmental disorder. Despite the difference in genetic causes, both ALS and SMA share common phenotypes; dysfunction/loss of motor neurons that eventually leads to muscle weakness and atrophy. With advanced techniques in molecular genetics and cell biology, current data suggest that these two distinct motor neuron diseases share more than phenotypes; ALS and SMA have similar cellular pathological mechanisms including mitochondrial dysfunction, oxidative stress and dysregulation in RNA-mediated gene expression. Here, we will discuss the current findings on these two diseases with specific focus on RNA-mediated gene regulation including miRNA expression, pre-mRNA processing and RNA binding proteins.
Keywords: Amyotrophic lateral sclerosis, microRNA, motor neuron disease, mRNA translation, RNA binding proteins, SMN, Spinal muscular atrophy, TDP-43/FUS.
CNS & Neurological Disorders - Drug Targets
Title:Dysregulation of RNA Mediated Gene Expression in Motor Neuron Diseases
Volume: 15 Issue: 8
Author(s): Inês do Carmo G. Gonçalves, Wiebke A. Rehorst and Min Jeong Kye
Affiliation:
Keywords: Amyotrophic lateral sclerosis, microRNA, motor neuron disease, mRNA translation, RNA binding proteins, SMN, Spinal muscular atrophy, TDP-43/FUS.
Abstract: Recent findings indicate an important role for RNA-mediated gene expression in motor neuron diseases, including ALS (amyotrophic lateral sclerosis) and SMA (spinal muscular atrophy). ALS, also known as Lou Gehrig’s disease, is an adult-onset progressive neurodegenerative disorder, whereby SMA or “children’s Lou Gehrig’s disease” is considered a pediatric neurodevelopmental disorder. Despite the difference in genetic causes, both ALS and SMA share common phenotypes; dysfunction/loss of motor neurons that eventually leads to muscle weakness and atrophy. With advanced techniques in molecular genetics and cell biology, current data suggest that these two distinct motor neuron diseases share more than phenotypes; ALS and SMA have similar cellular pathological mechanisms including mitochondrial dysfunction, oxidative stress and dysregulation in RNA-mediated gene expression. Here, we will discuss the current findings on these two diseases with specific focus on RNA-mediated gene regulation including miRNA expression, pre-mRNA processing and RNA binding proteins.
Export Options
About this article
Cite this article as:
Gonçalves do Carmo G. Inês, Rehorst A. Wiebke and Kye Jeong Min, Dysregulation of RNA Mediated Gene Expression in Motor Neuron Diseases, CNS & Neurological Disorders - Drug Targets 2016; 15 (8) . https://dx.doi.org/10.2174/1871527315666160815164808
DOI https://dx.doi.org/10.2174/1871527315666160815164808 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Differential Splicing, Disease and Drug Targets
Infectious Disorders - Drug Targets Immunological Mechanism and Clinical Application of PAMP Adjuvants
Recent Patents on Anti-Cancer Drug Discovery The Potential of PI3K/AKT/mTOR Signaling as a Druggable Target for Endometrial and Ovarian Carcinomas
Current Drug Targets Folate-Linked Lipid-Based Nanoparticle for Targeted Gene Delivery
Current Drug Delivery HIV-1 TAT and IMMUNE DYSREGULATION in AIDS PATHOGENESIS: a THERAPEUTIC TARGET
Current Drug Targets Targeted Nanosystems to Prostate Cancer
Current Pharmaceutical Design Investigating ABCB1-Mediated Drug-Drug Interactions: Considerations for In vitro and In vivo Assay Design
Current Drug Metabolism MicroRNA-34 Family, Mechanisms of Action in Cancer: A Review
Current Cancer Drug Targets Is Src a Viable Target for Treating Solid Tumours?
Current Cancer Drug Targets Influence of Tumor Microenvironment on the Distribution and Elimination of Nano-formulations
Current Drug Metabolism Molecular Mechanisms of Drug Photodegradation and Photosensitization
Current Pharmaceutical Design Pharmacotherapies to Manage Bone Loss-Associated Diseases: A Quest for the Perfect Benefit-to-Risk Ratio
Current Medicinal Chemistry Radiation Therapy in the Early 21st Century: Technological Advances
Current Cancer Therapy Reviews Potential Drug Targets on the HIV-1 Envelope Glycoproteins, gp120 and gp41
Current Pharmaceutical Design High-Throughput Techniques for Identifying microRNA Target Genes
Current Bioinformatics Accessing the Blood-Brain Barrier to Treat Brain Disorders
Current Nanomedicine Editorial [Hot Topic: Frontotemporal Lobar Degeneration and Related Disorders (Guest Editor: Barbara Borroni)]
Current Alzheimer Research Rediscovering Tocophersolan: A Renaissance for Nano-Based Drug Delivery and Nanotheranostic Applications
Current Drug Targets The Potential of Tetrandrine Against Gliomas
Anti-Cancer Agents in Medicinal Chemistry CD133 Expressing Pericytes and Relationship to SDF-1 and CXCR4 in Spinal Cord Injury
Current Neurovascular Research